Major Depressive Disorder Drug Market Ongoing Trends, Growth Prospects & Challenges by 2023

Major Depressive Disorder Drug In US Market Size, Share, Trends,
Company Profiles, Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast To 2023
Summary
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide.
The MDD market is a crowded and competitive market, with more than 30 marketed products
available for the treatment of patients with MDD. The depression market is about to enter a
dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's
Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal
antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of
seven promising late-stage pipeline products into the market during the forecast period, from
2013 to 2023.
The value of the US market is expected to fall following patent expiries for Eli Lilly's Cymbalta
in 2013, Otsuka Pharmaceutical/BMS's Abilify in 2015, and AstraZeneca's Seroquel XR in 2017.
After a period of declining sales, GlobalData estimates that the MDD market in the US will
follow a steady growth trend from 2018 to 2023.
Read Complete Report with TOC: http://www.radiantinsights.com/research/pharmapointmajor-depressive-disorder-us-drug-forecast-and-market-analysis-to-2023
Scope
- Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Major
depressive disorder market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major
depressive disorder.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug
performance
- Obtain sales forecast for drugs from 2013-2023 in the US.

Table Of Content:
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 12
2 Introduction 13
2.1 Catalyst 13
2.2 Related Reports 13
2.3 Upcoming Related Reports 15
3 Disease Overview 16
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 16
3.2 Classification 18
3.3 Symptoms and Subtypes of Major Depressive Disorder 20
3.4 Prognosis 21
3.5 Quality of Life 21
To Get Sample Copy of Report visit @
http://www.radiantinsights.com/research/pharmapoint-major-depressive-disorder-usdrug-forecast-and-market-analysis-to-2023#tabs-4
4 Disease Management 22
4.1 Diagnosis and Treatment Overview 22
4.1.1 Diagnosis 22
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 23
4.1.3 Clinical Practice 24
4.2 US 27
5 Competitive Assessment 30
5.1 Overview 30
5.2 Product Profiles: Major Brands, Selective Serotonin Reuptake Inhibitors 32
5.2.1 Lexapro (Escitalopram) 32
5.2.2 Viibryd (Vilazodone) 36
5.2.3 Other Selective Serotonin Reuptake Inhibitors 39
5.3 Product Profiles: Major Brands, Serotonin-Norepinephrine Reuptake Inhibitors 43
5.3.1 Effexor (Venlafaxine) 43
5.3.2 Cymbalta (Duloxetine) 46
5.3.3 Pristiq (Desvenlafaxine) 50
5.3.4 Fetzima (Levomilnacipran) 54
5.3.5 Savella (Milnacipran) 58
5.4 Product Profiles: Major Brands, Other Antidepressants 60
5.4.1 Norepinephrine-Dopamine Reuptake Inhibitors 60

5.4.2 Noradrenaline and Specific Serotonergic Antidepressants 64
5.4.3 Monoamine Oxidase Inhibitors 68
5.4.4 Tricyclic Antidepressants 70
5.4.5 Brintellix (Vortioxetine) 72
5.5 Product Profiles: Major Brands, Antipsychotics 78
5.5.1 Abilify (Aripiprazole) 78
5.5.2 Seroquel XR (Quetiapine) 82
5.6 Other Therapeutic Classes 86
6 Unmet Needs and Opportunities 87
6.1 Overview 87
6.2 More Effective Pharmacotherapies 88
6.2.1 Unmet Needs 88
6.2.2 Gap Analysis 89
6.2.3 Opportunities 90
6.3 More Favorable Side Effect Profiles 90
6.3.1 Unmet Needs 90
6.3.2 Gap Analysis 91
6.3.3 Opportunities 91
6.4 Rapid Onset of Antidepressant Effects 92
6.4.1 Unmet Needs 92
6.4.2 Gap Analysis 92
6.4.3 Opportunities 92
6.5 Personalized Treatment Approach 93
6.5.1 Unmet Needs 93
6.5.2 Gap Analysis 94
6.5.3 Opportunities 94
Browse All Reports of This Category @
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
7 Pipeline Assessment 95
7.1 Overview 95
7.2 Promising Drugs in Clinical Development 95
7.2.1 Brexpiprazole (OPC-34712) 98
7.2.2 Cariprazine (RGH-188) 104
7.2.3 ALKS-5461 109
7.2.4 Amitifadine (EB-1010) 114
7.2.5 GLYX-13 119
7.2.6 Tedatioxetine (Lu AA24530) 123
7.2.7 ETS6103 127
7.3 Other Drugs in Development 132
8 Market Outlook 134
8.1 US 134
8.1.1 Forecast 134

8.1.2 Key Events 138
8.1.3 Drivers and Barriers - Global Issues 138
8.1.4 Drivers and Barriers 140
9 Appendix 143
9.1 Bibliography 143
9.2 Abbreviations 148
9.3 Methodology 152
9.4 Forecasting Methodology 152
9.4.1 Diagnosed MDD Patients 152
9.4.2 Percent of Drug-Treated Patients 152
9.4.3 Drugs Included in Each Therapeutic Class 153
9.4.4 Launch and Patent Expiry Dates 153
9.4.5 General Pricing Assumptions 154
9.4.6 Individual Drug Assumptions 154
9.4.7 Generic Erosion 159
9.4.8 Pricing of Pipeline Agents 159
9.5 Physicians and Specialists Included in this Study 161
9.6 About the Authors 163
9.6.1 Analyst 163
9.6.2 Therapy Area Directors 163
9.6.3 Global Head of Healthcare 164
9.7 About GlobalData 165
9.8 Disclaimer 165
About Us
Radiant Insights is a platform for companies looking to meet their market research and business
intelligence requirements. We assist and facilitate organizations and individuals procure market
research reports, helping them in the decision making process. We have a comprehensive
collection of reports, covering over 40 key industries and a host of micro markets. In addition to
over extensive database of reports, our experienced research coordinators also offer a host of
Ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Website: Radiant Insights
Visit Our Blog: radiantri.blogspot.com